| Catalog No. |
Size |
Price |
Figures |
|---|
Z00342-10 ug
| 10 ug | $ 91.00 |
References:
- Okamoto H, et al. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Lung Cancer. Aug 2006; 53(2): 197-203.
- Zhang Y, et al. Synergistic effects of granulocyte-colony stimulating factor and macrophage-colony stimulating factor on recovery of donor hematopoietic cells in allogeneic bone marrow transplantation. Oncol. Rep. Aug 2006; 16(2): 367-371.
|
|---|
Z00342-50 ug
| 50 ug | $ 320.00 |
|---|
Z00342-1 mg
| 1 mg | $ 1600.00 |
|---|
| Full Name | | Granulocyte Colony Stimulating Factor (G-CSF), human |
|
| Abbreviated Name-1 | rHuG-CSF |
|---|
| Abbreviated Name-2 | G-CSF |
|---|
| Description | Granulocyte Colony Stimulating Factor (G-CSF), human contains internal disulfide bonds. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. The synthesis of G-CSF can be induced by bacterial endotoxins, TNF, Interleukin-1 and GM-CSF. Prostaglandin E2 inhibits the synthesis of G-CSF. In epithelial, endothelial, and fibroblastic cells secretion of G-CSF is induced by Interleukin-17.
Recombinant Human G-CSF produced in E. coli is a single, non-glycosylated, polypeptide chain containing 175 amino acids and having a molecular mass of 18,800 Da.
|
|---|
| Source | E. coli |
|---|
| M.W. | 18,800 Da |
|---|
| Isoelectric Point | The main zone between 5.8-6.6 analysis by IEF |
|---|
| UV Scan | The maximal absorption wave is 278+/-3 nm. |
|---|
| Purity | Greater than 95% as determined by:
(a) Analysis by SEC-HPLC
(b)Analysis by reducing and non-reducing SDS-PAGE silver-stained gel |
|---|
| Endotoxin Level | Less than 0.1 ng/μg (IEU/μg) of rHuG-CSF |
|---|
| Specific Activity | The specific activity was greater than 6.0×107 IU/mg. |
|---|
| Storage | Lyophilized rHuG-CSF although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution rHuG-CSF should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles. |
|---|
| Formulation | The protein was lyophilized after extensive dialysis against 10 mM sodium acetate buffer pH 4. |
|---|
| Reconstitution | It is recommended to reconstitute the lyophilized rHuG-CSF in sterile 18 MΩ-cm H2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. |
|---|
| Quantitation | Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm using the absorbency value of 0.815 as the extinction coefficient for a 0.1% (1 mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a standard solution of recombinant G-CSF as a Reference Standard.
|
|---|
| Sequence analysis | The sequence of the first fifteen N-terminal amino acids was determined and was found to be Met-Thr-Pro-Leu-Gly-Pro-Ala-Ser-Ser-Leu-Pro-Gln-Ser-Phe-Leu-Leu.
|
|---|
